

Code	Code Description	Z1 Fee on File Medicaid Rate (Current Fees in Red)				O1 Outpatient Hospital Rate (Current Fees in Red)			
		Effective Begin Date	Fee	Effective Dates	Fee	Effective Begin Date	Fee	Effective Dates	Fee
0001A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 30 MCG/0.3ML DOSAGE, DILUENT RECONSTITUTED; FIRST DOSE	Effective Begin Date 3/15/2021	\$35.87	Effective Dates 12/11/2020-3/14/2021	\$16.94	Effective Begin Date 2/1/2021	\$15.50	Effective Dates 12/11/2020-1/31/2021	\$16.94
0002A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 30 MCG/0.3ML DOSAGE, DILUENT RECONSTITUTED; SECOND DOSE	Effective Begin Date 3/15/2021	\$35.87	Effective Dates 12/11/2020-3/14/2021	\$28.39	Effective Begin Date 2/1/2021	\$25.50	Effective Dates 12/11/2020-1/31/2021	\$28.89
0003A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 30 MCG/0.3 ML DOSAGE, DILUENT RECONSTITUTED; THIRD DOSE	Effective Begin Date 8/12/2021	\$35.87	N/A	N/A	Effective Begin Date 8/12/2021	\$31.26	N/A	N/A
0011A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 100 MCG/0.5ML DOSAGE; FIRST DOSE	Effective Begin Date 3/15/2021	\$35.87	Effective Dates 12/18/2020-3/14/2021	\$16.94	Effective Begin Date 2/1/2021	\$15.50	Effective Dates 12/18/2020-1/31/2021	\$16.94
0012A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 100 MCG/0.5ML DOSAGE; SECOND DOSE	Effective Begin Date 3/15/2021	\$35.87	Effective Dates 12/18/2020-3/14/2021	\$28.39	Effective Begin Date 2/1/2021	\$25.50	Effective Dates 12/18/2020-1/31/2021	\$28.89
0013A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 100 MCG/0.5 ML DOSAGE; THIRD DOSE	Effective Begin Date 8/12/2021	\$35.87	N/A	N/A	Effective Begin Date 8/12/2021	\$31.26	N/A	N/A
0031A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, DNA, SPIKE PROTEIN, ADENOVIRUS TYPE 26 (AD26) VECTOR, PRESERVATIVE FREE, 5x10^10 VIRAL PARTICLES/0.5ML DOSAGE, SINGLE DOSE	Effective Begin Date 3/15/2021	\$35.87	Effective Dates 2/27/2020-3/14/2021	\$28.39	Effective Begin Date 2/27/2021	\$28.89	N/A	N/A
M0239	INTRAVENOUS INFUSION, BAMLANIVIMAB-XXXX, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING	Effective Begin Date 11/10/2020	\$278.64	N/A	N/A	Effective Begin Date 2/1/2021	\$242.88	Effective Dates 11/10/2020-1/31/2021	\$278.64
M0240	INTRAVENOUS INFUSION OR SUBCUTANEOUS INJECTION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION OR INJECTION, AND POST ADMINISTRATION MONITORING, SUBSEQUENT REPEAT DOSES	Effective Begin Date 7/30/2021	\$343.60	N/A	N/A	Effective Begin Date 7/30/2021	\$343.60	N/A	N/A
M0243	INTRAVENOUS INFUSION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION AND POST ADMINISTRATION MONITORING	Effective Begin Date 11/21/2020	\$237.50	N/A	N/A	Effective Begin Date 2/1/2021	\$242.88	Effective Dates 11/21/2020-1/31/2021	\$278.64
M0245	INTRAVENOUS INFUSION, BAMLANIVIMAB AND ETESEVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING	Effective Begin Date 2/9/2021	\$237.50	N/A	N/A	Effective Begin Date 4/1/2021	\$242.88	Effective Dates 2/9/2021-3/31/2021	\$278.64
M0249	INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH COVID-19 WHO ARE RECEIVING SYSTEMIC CORTICOSTEROIDS AND REQUIRE SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) ONLY, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING, FIRST DOSE	Effective Begin Date 6/24/2021	\$343.60	N/A	N/A	Effective Begin Date 6/24/2021	\$343.60	N/A	N/A
M0250	INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH COVID-19 WHO ARE RECEIVING SYSTEMIC CORTICOSTEROIDS AND REQUIRE SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) ONLY, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING, SECOND DOSE	Effective Begin Date 6/24/2021	\$349.00	N/A	N/A	Effective Begin Date 6/24/2021	\$349.00	N/A	N/A